New Benchmark for Targeted Therapies in Lung Cancer: Median Progression-Free Survival for Lorlatinib in Advanced ALK+ Non-Small Cell Lung Cancer Surpasses 5 years.
Christine M LovlyPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)